Treatment for Secondary FSGS Due to Diabetes

Introduction to Secondary FSGS

• Secondary FSGS due to diabetes differs fundamentally from primary FSGS in both pathophysiology and treatment approach, with key features including diabetes history and specific histological variants 1, 2
• The American Journal of Kidney Diseases recommends that immunosuppressive therapy is generally not recommended for secondary FSGS as it provides minimal benefit while exposing patients to significant risks 3, 4

First-Line Treatment Approach

• The Kidney International guidelines suggest that ACE inhibitors or ARBs should be the cornerstone of therapy for diabetic secondary FSGS, with a target blood pressure of ≤125/80 mmHg 1
• Aggressive blood pressure control is essential for slowing disease progression, and may require combination therapy with thiazide diuretics and/or loop diuretics 1, 2

Additional Therapeutic Considerations

• Statin therapy is recommended for cardiovascular risk reduction, and helps manage hyperlipidemia commonly associated with proteinuric kidney disease 1
• Sodium restriction can enhance antihypertensive and antiproteinuric effects of medications, and weight loss in obese patients can help reduce hyperfiltration injury 1, 2

When to Consider Immunosuppression

• The American Journal of Kidney Diseases guidelines explicitly recommend that immunosuppressive therapy should NOT be used for secondary FSGS due to diabetes, and should only be considered in idiopathic FSGS associated with clinical features of the nephrotic syndrome 5, 3, 6, 7
• If proteinuria persists despite optimal conservative management, re-evaluation of diagnosis may be warranted before considering immunosuppression 1, 8

Monitoring and Follow-up

• Persistent high-grade proteinuria despite optimal conservative management suggests poor prognosis, according to the Kidney International guidelines 1
• The Kidney International guidelines also recommend regular monitoring of proteinuria, serum creatinine, and estimated GFR, although the exact frequency is not specified 1

Common Pitfalls to Avoid

• Misdiagnosing secondary FSGS as primary FSGS can lead to inappropriate immunosuppressive therapy, as noted in the Kidney International and American Journal of Kidney Diseases guidelines 2, 3
• Inadequate dosing of ACE inhibitors/ARBs and failing to address all modifiable risk factors can also worsen outcomes, according to the Kidney International guidelines 1